The pharmaceutical industry is almost boundless in its ability to supply new drug therapies, but how does one decide which are the best medicines to use within restricted budgets? With particular emphasis on modeling, methodologies, data sources, and application to real-world dilemmas, Pharmacoeconomics: From Theory to Practice provides an introduction to the major concepts and principles of pharmacoeconomics and cost-effectiveness analysis (CEA).
As a running theme, the book explores the collaboration among members of the pharmaceutical industry, academia, and government in the development of the human papillomavirus vaccine to demonstrate the full range of ethical and moral issues, as well as overall public health and commercial concerns that are often involved in decisions entailing CEA. Readers will learn about the international use of pharmacoeconomics in drug regulation, drug approval, and pricing, and the book provides examples of pharmacoeconomic models used to support these purposes in government, the pharmaceutical industry, and healthcare settings.
In this era of finite budgets, healthcare rationing, medication shortages, and the global aging and burgeoning of populations, numerous stakeholders in the healthcare arena must understand the basic principles of pharmacoeconomics and how these may be correctly applied to facilitate drug development, drug approval, rationing, patient segmentation, disease management, and pricing model development. Focusing on how to save money, not by restricting access to necessary services, but by using available resources more efficiently and rationally, this volume arms decision makers with the tools they need to make wise choices in an area where the stakes are so high.
'Pharmacoeconomics: From Theory to Practice is one of an expanding collection of books on pharmacoeconomics, health economics, and decision analysis available to pharmacy educators. This one is a contribution to that collection due to its content and quality of writing. Although the book is an introduction, individuals with experience in pharmacoeconomics may benefit from reading it, too.'
– David A. Holdford, PhD, School of Pharmacy, Virginia Commonwealth University, for American Journal of Pharmaceutical Education, 2010; 74 (3) Article 53.
‘In my view, this is a simple and useful book and a research tool. … This book can serve as a textbook, but also can be used as a self-learning tool. … a new researcher can easily follow the book without a personal guide. … Different from other textbooks, this book spent a large amount of text discussing the applications of pharmacoeconomics theory into real world practices. This is very helpful for those readers that need to apply it to their daily research. It was a pleasurable reading experience.’
– Boxiong Tang, MD, PhD, Senior Director, GHEOR.
Introduction to Pharmacoeconomics, W. F. McGhan
Decision Modeling Techniques, M. S. Roberts and K. J. Smith
Cost of Illness, R. J. G. Arnold
Markov Modeling in Decision Analysis, J. R. Beck
Retrospective Database Analysis, R. J. G. Arnold and S. Balu
What is Cost-Minimization Analysis?, A. Haycox
Cost-Effectiveness Analysis, K. J. Smith and M. S. Roberts
Budget Impact Analysis, L. Annemans
Cost-Utility Analysis: A Case Study of a Quadrivalent Human Papillomavirus Vaccine, E. J. Dasbach, R. P. Insinga, and E. H. Elbasha
Some Problems/Assumptions in Pharmacoeconomic Analysis, S. Birks
Patient-Reported Outcome Measures, D. Bryant, G. Guyatt, and R. J. G. Arnold
Sensitivity Analysis, M. J. Postma
Use of Pharmacoeconomics in Drug Reimbursement in Australia, Canada, and the United Kingdom: What Can We Learn from International Experience?, M. Drummond and C. Sorenson
Pharmacoeconomics in Disease Management: Practical Applications and Persistent Challenges, R. Suh and D. Atkins
Computer Aided Decision Making from Drug Discovery to Pharmacoeconomics, S. Ekins and R. J. G. Arnold
Speculations on the Future Challenges and Value of Pharmacoeconomics, J. J. Caro, D. Getsios, and R. L. Fleurence